Alena Gros

Has grant

Group Leader

Vall d'Hebron Institute of Oncology
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Non-invasive personalized T-cell therapies targeting recurrent hot spot driver mutations in cancer

Open Date: 2018-06-01

Close Date: 2020-05-01

Grant: Close

Identification of non-canonical tumor antigens and analysis of their importance in cancer immunotherapy: immunogenicity and predictive value

Open Date: 2018-01-01

Close Date: 2020-12-01

Grant: Close

Identification of biomarkers of response to cancer immunotherapy in liquid biopsies: phenotypic and functional landscape of circulating PD-1+ lymphocytes.

Open Date: 2017-12-01

Close Date: 2020-11-01

Grant: Close

Personalized non-invasive T-cell therapies targeting the mutanome.

Open Date: 2017-12-01

Close Date: 2020-11-01

Grant: Close

Characterization of neaontigen-specific T cells and identification of predictive biomarkers of response in patients with MSI and MSI-like CRC treated with anti-PD-L1.

Open Date: 2016-04-01

Close Date: 2019-12-01

Articles (7)

Year:

2025

Supplementary Figure 1. Validation of HLA-I ligand tumor antigen candidates with synthetic peptidesSupplementary Figure 2. Validation of selected HLA-I ligand tumor antigen candidates identified in Mel-1 and Mel-3 with isotope-labeled peptidesSupplementary Figure 3. Frequency of nonC peptides detected in HLA-I.Supplementary Fig. 4. HLA-I allele binding motif of all patients included in the study.Supplementary Figure 5. A fraction of nonC-TL can be detected in publicly available immunopeptidomics datasets from human tumor biopsiesSupplementary Figure 6. Evaluation of pre-existing T-cell responses to candidate tumor antigens in cancer patientsSupplementary Figure 7. Enrichment of antigen-specific T cells from cancer patients by flow cytometry-based sorting.Supplementary Figure 8. Deconvolution of peptide pools containing recognized CGA or melanoma-associated antigens.Supplementary Figure 9. Functional avidity and specificity of neoantigen-specific T cells isolated from cancer patients.Supplementary Figure 10. HLA restriction element and recognition of autologous tumor cell lines by antigen-specific T cells isolated from cancer patients.SupplementaryFigure 11. Genomic location of the three immunogenic nonC-TL identified through IVS.Supplementary Figure 12. Recognition of the predicted ORFs encoding the immunogenic nonC-TL by TCR transduced cells.Supplementary Figure 13. Loss of recognition of TCL transfected with Cas9-sgRNA targeting the predicted 5’U-HOXC13 ORF.Supplementary Figure 14. Assessment of expression and translation of the immunogenic nonC-TL in human healthy cells.Supplementary Figure 15. NonC-TL are the main source of candidate tumor antigens identified by proteogenomics but tumor-reactive T cells preferentially recognize neoantigens derived from NSM.

Year:

2025

Tissue biomarker analyses and the VIGex score. A, Immune tumor contexture of the basal samples and surgical specimens in patients with MPR ( n = 8) and without MPR ( n = 25). B, Gene expression profile on surgical specimens, integrated within the VIGex score, and individual gene expression profile on surgical specimens. CK, cytokeratin; Post-ttm, posttreatment.

Year:

2025

Purpose: Immune checkpoint inhibitors combined with chemotherapy have provided successful results in patients with gastric and gastroesophageal junction (G/GEJ) cancers in the metastatic setting. Similar strategies have been explored in earlier stages. In this study, we present the final results of the phase II MONEO trial, which evaluated the addition of avelumab to neoadjuvant chemotherapy. Patients and Methods: Patients with untreated, resectable G/GEJ adenocarcinoma received neoadjuvant treatment with four cycles of avelumab plus the FLOT4 regimen, followed by surgery. Upon postoperative recovery, patients underwent four additional adjuvant cycles of the same combination, followed by avelumab monotherapy for up to 1 year. The primary endpoint was pathologic complete response rate. Sequential flow cytometry and cytokine determination were performed in peripheral blood, along with multiplex tissue immunofluorescence and RNA sequencing in tumor specimens. Results: Forty patients were enrolled, achieving a pathologic complete response rate of 21.1% (95% confidence interval, 10.0–37.0). The major pathologic response rate was 28.9%, more pronounced in patients with tumors expressing PD-L1 before treatment as measured by the combined positive score (cutoff, 10; 33.3% vs. 21.1%). The results propose several potential biomarkers considering tumor immune infiltrate, circulating immune cells, and cytokines. Eighty percent of patients experienced treatment-related grade ≥3 adverse events. Conclusions: The combination of avelumab plus the FLOT4 regimen showed relatively modest efficacy in resectable G/GEJ adenocarcinoma. Better results were observed in PD-L1 combined positive score ≥10% tumors. Exploratory biomarker analyses provide insights that may help to identify candidates most likely to benefit from chemoimmunotherapy as a neoadjuvant treatment.

Year:

2025

Analyses on circulating cytokines and leukocytes. A, Mean difference in peripheral cytokines (fold change) at cycle 1, cycle 2, and at presurgery evaluation between patients with MPR ( n = 11) and without MPR ( n = 25). B, Peripheral immune cells quantified as percentages and compared baseline and posttreatment results showing the difference between pCR ( n = 3) and non-pCR ( n = 8) patients, with the delta in patients with pCR as indicated. Positive (green) or negative (red) differences are color-coded, and the magnitude is reflected by the intensity of the color. MDSC, myeloid-derived suppressor cell; PBM, peripheral blood mononuclear; PMN, polymorphonuclear; TR/EG, regulatory T cells.

Year:

2025

Efficacy endpoints. A, Percentage of tumor regression grade. B, Tumor regression grade depending on PD-L1 CPS, HER2, and MMR status. C, PFS. D, OS. E, Subgroup analysis for PFS. F, Subgroup analysis for OS. pMMR, MMR-proficient.

Year:

2025

Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of nonC tumor HLA-I ligands (nonC-TL) to better understand their contribution to cancer immunosurveillance and their therapeutic applicability. Experimental Design: Peptides presented on HLA-I were identified in 9 patient-derived tumor cell lines from melanoma, gynecologic, and head and neck cancer through proteogenomics. A total of 507 candidate tumor antigens, including nonC-TL, neoantigens, cancer-germline, or melanocyte differentiation antigens, were tested for T-cell recognition of preexisting responses in patients with cancer. Donor peripheral blood lymphocytes (PBL) were in vitro sensitized against 170 selected nonC-TL to isolate antigen-specific T-cell receptors (TCR) and evaluate their therapeutic potential. Results: We found no recognition of the 507 nonC-TL tested by autologous ex vivo expanded tumor-reactive T-cell cultures while the same cultures demonstrated reactivity to mutated, cancer-germline, or melanocyte differentiation antigens. However, in vitro sensitization of donor PBL against 170 selected nonC-TL, led to the identification of TCRs specific to three nonC-TL, two of which mapped to the 5′ UTR regions of HOXC13 and ZKSCAN1 , and one mapping to a noncoding spliced variant of C5orf22C . T cells targeting these nonC-TL recognized cancer cell lines naturally presenting their corresponding antigens. Expression of the three immunogenic nonC-TL was shared across tumor types and barely or not detected in normal cells. Conclusions: Our findings predict a limited contribution of nonC-TL to cancer immunosurveillance but demonstrate they may be attractive novel targets for widely applicable immunotherapies. See related commentary by Fox et al., p. 2173

Year:

2025

Collaborators (16)

Maria Carmen Ochoa

Associate researcher

Center for Applied Medical Research

SPAIN
View details

Mariano Ponz-Sarvise

Universidad de Navarra

SPAIN
View details

Andreas Schlosser

-

GERMANY
View details

Julio Delgado

Head

Hospital Clínic de Barcelona

SPAIN
View details

Ana Vivancos

Principal Investigator

Vall d'Hebron Institute of Oncology

SPAIN
View details

Ignacio Matos

Clinica Universidad de Navarra

SPAIN
View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Elena Garralda

Director

-

SPAIN
View details

Guillermo Villacampa Javierre

Biostatistician

Vall d´Hebron Institute of Oncology

SPAIN
View details

Florian Erhard

Chair of Computational Immunology

University of Regensburg

GERMANY
View details

Paula Jimenez-Fonseca

Central University Hospital of Asturias

SPAIN
View details

August Vidal

Professor Associat Mèdic

University of Barcelona

SPAIN
View details

Sonia Guedan Carrio

Principal Investigator

Institut d'Investigacions Biomèdiques August Pi i Sunyer

SPAIN
View details

Carlos E de Andrea

-

SPAIN
View details

Jared Gartner

National Institutes of Health

UNITED STATES
View details